Clinical observation of salmeterol /fluticasone propionate combined with tiotropium bromide in the treatment of COPD patients at stable stage

Objective To observe the efficacy of different doses of salmeterol/fluticasone propionate combined with tiotropium bromide in the treatment of COPD patients at stable stage. Methods 90 patients with moderate to severe COPD at stable stage were randomly divided into three groups. The group A inhaled tiotropium bromide( 18 μg once daily) alone. The group B inhaled salmeterol / fluticasone propionate( 50 /250 μg twice daily) and tiotropium bromide( 18 μg once daily). The group C inhaled salmeterol / fluticasone propionate( 50 /500 μg twice daily) and tiotropium bromide( 18 μg once daily). The total treatment course was 12 weeks,and pulmonary function,6-minute walk test(6MWT) and MMRC score were detected and compared among the three groups before and after the treatment. Results There was no significant improvement of pulmonary function,6MWTand MMRC score in the group A after the treatment( P 0. 05). The moderate COPD patients in the group B had significant improvement on pulmonary function,6MWTand MMRC score( P 0. 05),but there was no significant improvement to the severe patients in the group B( P 0. 05). The group C showed significant improvement( P 0. 05),but the moderate patients in the group C had less benefit than those in the group B. Conclusion Salmeterol / fluticasone propionate combined with tiotropium bromide has a certain curative effect in the treatment of COPD patients were certain,which can reduce the economic burden of patients and drug side reactions.